Abstract |
We evaluated the tumor response and survival according to the KRAS oncogene status in locally advanced rectal cancer. One hundred patients with locally advanced rectal cancer (cT3-4N0-2M0) received preoperative radiation of 50.4 Gy in 28 fractions with 5-fluorouracil and total mesorectal excision. Tumor DNA from each patient was obtained from pretreatment biopsy tissues. A Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation was found in 26 (26%) of the 100 patients. Downstaging (ypT0-2N0M0) rates after preoperative chemoradiotheray were not statistically different between the wild-type and mutant-type KRAS groups (30.8% vs 27.0%, P = 0.715, respectively). After a median follow-up time of 34 months, there was no statistically significant difference in the 3-year relapse-free survival (82.2% vs 82.6%, P = 0.512) and overall survival (94.7% vs 92.3%, P = 0.249) rates between wild-type and mutant-type KRAS groups, respectively. The KRAS mutation status does not influence the tumor response to the radiotherapy and survival in locally advanced rectal cancer patients who received preoperative chemoradiotherapy and curative surgery.
|
Authors | Jeong Won Lee, Jong Hoon Lee, Byoung Yong Shim, Sung Hwan Kim, Mi-Joo Chung, Bong-Hyeon Kye, Hyung Jin Kim, Hyeon Min Cho, Hong Seok Jang |
Journal | Medicine
(Medicine (Baltimore))
Vol. 94
Issue 31
Pg. e1284
(Aug 2015)
ISSN: 1536-5964 [Electronic] United States |
PMID | 26252300
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- KRAS protein, human
- Proto-Oncogene Proteins
- Pyrimidines
- 5-fluoropyrimidine
- Proto-Oncogene Proteins p21(ras)
- ras Proteins
|
Topics |
- Adenocarcinoma
(genetics, mortality, therapy)
- Aged
- Chemoradiotherapy, Adjuvant
- Disease-Free Survival
- Female
- Humans
- Male
- Middle Aged
- Mutation
(genetics)
- Proto-Oncogene Proteins
(genetics)
- Proto-Oncogene Proteins p21(ras)
- Pyrimidines
(therapeutic use)
- Rectal Neoplasms
(genetics, mortality, therapy)
- Retrospective Studies
- Survival Rate
- Treatment Outcome
- ras Proteins
(genetics)
|